Therapy News and Research

RSS

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Cell division is an essential process for the development of an organism. This process, however, can cause tumour growth when it stops working properly. Tumour cells accumulate alterations in their genetic material, and this makes them divide in an uncontrolled fashion, thus encouraging growth of the tumour.

9 Oct 2013

Recent study confirms healing properties of liquorice in lung surgery patients

In Traditional Chinese Medicine (TCM), liquorice is regarded as a "panacea". A recent study by the University Department of Anaesthetics, General Intensive Care Medicine and Pain Therapy at the MedUni Vienna has now, for the first time, scientifically confirmed the healing properties of this natural substance.

9 Oct 2013

ProTip, Strasbourg University Hospitals complete first implantation of artificial larynx in human patient

ProTip SAS, the specialist developer of innovative medical devices for patients suffering from laryngeal malfunction, and Strasbourg University Hospitals today announce that they have successfully completed the first implantation of an artificial larynx in a human patient.

9 Oct 2013

Evaluate launches strategic sales analytics solution that provides global view of life sciences product sales

Evaluate Ltd. today announced the launch of a strategic sales analytics solution that provides commercial teams and the investment community with a comprehensive view of life sciences product sales by country.

9 Oct 2013

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

NeuroVigil, Inc. is setting to collaborate with a number of partners in the Silicon Valley where it is opening a satellite research laboratory at NASA Research Park in Mountain View, CA, to develop assistive technologies for individuals suffering from ALS and other conditions affecting the central nervous system.

9 Oct 2013

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Healios K.K. (Headquarters: Tokyo, Japan; President and CEO: Hardy TS Kagimoto M.D.), a Japanese bioventure company at the forefront of developing innovative therapies utilizing human induced pluripotent stem cell (hiPSC) technology, is pleased to announce that it has successfully raised its target capital of 3 billion JPY (USD $30.6 million).

9 Oct 2013

Mitsubishi Electric to provide proton beam therapy system to Hakuhokai Group healthcare organization

Mitsubishi Electric Corporation announced today that it will provide its innovative proton beam therapy system for cancer treatment to the Hakuhokai Group healthcare organization led by Chairman Motohisa Kojo in Osaka, Japan. The system will be installed at the Hakuhokai Group Osaka Proton Therapy Clinic scheduled to open in April 2016.

9 Oct 2013

EGS announced that enrollment for RESPECT study has surpassed company's original target

EndoGastric Solutions (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that enrollment for the RESPECT study (Randomized EsophyX vs. Sham/Placebo Controlled Trial) is complete and has surpassed the company's original target of 120 patients.

9 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Laborie acquires UroMed's pelvic muscle rehabilitation business

Laborie Medical Technologies, Inc., a portfolio company of Audax Group, announced it has completed the acquisition of UroMed Technology, Inc.'s pelvic muscle rehabilitation business.

9 Oct 2013

ReAttach therapy can be effective treatment for people with autism

"ReAttach" is a new intervention, based on "attachment". Practical research has pointed out that the "ReAttach therapy" can be of great importance for people with autism. This is concluded from the continuous practical research of Paula Bartholomeus into the advantages that can be reached for people with Asperger's syndrome, PDD-NOS, autism spectrum disorder, or with a mental disability and autism, using the ReAttach therapy.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

The Melanoma Research Foundation Breakthrough Consortium has launched a new clinical trial to assess the impact of concomitant administration of bevacizumab (Avastin) with vemurafenib (Zelboraf) in patients with BRAFV600 mutation positive metastatic melanoma.

8 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

Metastatic site impacts survival in targeted RCC treatment

Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium.

8 Oct 2013

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Professor Richard Pleass has won the Prix de l’Innovation 2013, also known as the Universal Biotech Innovation Prize 2013.

8 Oct 2013

Personalised therapy can reduce risk of cardiac disease among diabetes patients

600,000 to 800,000 Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular disease can be determined even though their hearts appear to be healthy.

8 Oct 2013

In South Africa, rapid progress in reducing under-five mortality

Over the past decade, South Africa has made a dramatic reversal in child survival-mainly because of improvements in HIV/AIDS care, reports a study in AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

8 Oct 2013

Two researchers receive $2.5M grant to continue their research on cancer cell growth

A pair of researchers at Rutgers Cancer Institute of New Jersey has been awarded nearly $2.5 million dollars to further study in their respective laboratories.

8 Oct 2013

Therapy News and Research

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Recent study confirms healing properties of liquorice in lung surgery patients

ProTip, Strasbourg University Hospitals complete first implantation of artificial larynx in human patient

Evaluate launches strategic sales analytics solution that provides global view of life sciences product sales

NeuroVigil opens satellite research lab at NASA to develop assistive technologies for ALS

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Mitsubishi Electric to provide proton beam therapy system to Hakuhokai Group healthcare organization

EGS announced that enrollment for RESPECT study has surpassed company's original target

Bayer HealthCare receives FDA approval for Adempas tablets

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Laborie acquires UroMed's pelvic muscle rehabilitation business

ReAttach therapy can be effective treatment for people with autism

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

MRFBC launches clinical trial to assess impact of bevacizumab and vemurafenib in melanoma patients

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Metastatic site impacts survival in targeted RCC treatment

LSTM professor wins Universal Biotech Innovation Prize 2013 for Hexagard

Personalised therapy can reduce risk of cardiac disease among diabetes patients

In South Africa, rapid progress in reducing under-five mortality

Two researchers receive $2.5M grant to continue their research on cancer cell growth

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News